Benchling Exposure to Biotech Funding

Benchling is exposed less to whether scientists like the product, and more to whether biotech companies can afford to keep labs staffed and programs alive. Benchling sells seats, workflow modules, and later stage process software into customer R&D teams, so when a startup freezes hiring, kills a drug program, or shuts down, usage can flatten or disappear even if the software is already woven into daily lab work.1 2 3 4 5

• Benchling’s growth has been tied to customer expansion inside biotech orgs. Benchling said in 2021 that it served over 600 companies, including 22 of the 50 largest global biopharma companies, and later described its footprint as 1,200 plus customers and 200,000 plus scientists. That model works best when customers are adding people and programs.1 2 3
• Biotech downturns cut exactly the inputs that drive Benchling expansion. Industry coverage in 2023 and 2024 described layoffs, liquidations, canceled or delayed trials, and cash runway management as common responses to tighter funding. For a lab software vendor, that means fewer seats, fewer new teams to onboard, and less pull for adjacent products.4 5 6 7
• Benchling has some insulation because larger pharma customers are steadier buyers than venture funded startups. Internal research shows top 50 biopharmas grew from 23% of new revenue in 2019 to 43% in 2021, which means part of the playbook has been shifting mix toward bigger, better funded accounts that keep spending through biotech funding cycles.3 1

Going forward, the key question is whether Benchling keeps moving upmarket fast enough to offset volatility in startup biotech. If more revenue comes from big pharma, development, manufacturing, and AI linked workflows, Benchling becomes less dependent on the funding cycle of small research teams and more like core infrastructure for the whole drug pipeline.1 2 3